Cell Signaling Technology

Product Pathways - Growth Factors/Cytokines

Human Insulin-like Growth Factor I (hIGF-I) #8917

hIGF-1   hIGF1   hIGFI   IGFI  

No. Size Price
8917LC 250 µg ( With Carrier ) ¥6,860.00 现货查询 购买询价
8917LF 250 µg ( Carrier Free ) ¥6,860.00 现货查询 购买询价
8917SC 50 µg ( With Carrier ) ¥2,321.00 现货查询 购买询价
8917SF 50 µg ( Carrier Free ) ¥2,321.00 现货查询 购买询价
8917 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype

Species cross-reactivity is determined by western blot.

Applications Key:

Source / Purification

Recombinant human IGF-I (hIGF-I) Gly49-Ala118 (Accession #P01343) was produced in E. coli at Cell Signaling Technology.

CST公司生产的人源重组蛋白IGF-I (hIGF-I) Gly49-Ala118 (Accession #P01343)是从大肠杆菌细胞表达而来。

Molecular Characterization

Recombinant hIGF-I has a Met on the amino terminus and has a calculated MW of 7,785. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal MGPET of recombinant hIGF-I was verified by amino acid sequencing.

重组的hIGF-I蛋白在末端有Met标签,其分子量据推算为7,785Da。DTT-降解蛋白作为一个6kDa的蛋白而转移。重组hIGF-I蛋白的N-末端MGPET的序列通过测序得到。

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIGF-I. All lots are greater than 98% pure.

6 μg 还原 (+) 和 非还原的(-) hIGF-I通过SDS-PAGE检测,纯度大于98%,所有批次的纯度均高于98%。

Bioactivity

The bioactivity of recombinant hIGF-I was determined in a cell proliferation assay using primary human dermal fibroblasts. The ED50 of each lot is between 2-8 ng/ml.

重组蛋白hIGF-I的生物活性是通过人源皮肤成纤维细胞的增殖实验确定的。每个批次的ED50值在2-8 ng/ml之间。

Coomassie Gel

Coomassie Gel

The purity of recombinant hIGF-I was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIGF-I and staining overnight with Coomassie Blue.重组hIGF-I蛋白的纯度通过SDS-PAGE 来确定。6 µg 经降解(+)和未经过降解(-) 的重组hIGF-I蛋白跑SDS胶并用考马斯亮蓝染色过夜。

Western Blotting

Western Blotting

Western blot analysis of extracts from MCF-7 cells, untreated or treated with hIGF-I for 10 minutes, using Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (upper) and Akt1 (C73H10) Rabbit mAb #2938 (lower).Western免疫印迹。用Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (上图) 和 Akt1 (C73H10) Rabbit mAb #2938(下图) 研究未经处理的和经hIGF-I处理10 min的MCF-7 细胞的细胞提取液。

Bioactivity

Bioactivity

The proliferation of primary human dermal fibroblasts treated with increasing concentrations of hIGF-I was assessed. After 72-hour treatment with hIGF-I cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.在hIGF-I蛋白浓度递增条件下研究皮肤成纤维细胞增殖实验。用hIGF-I培养细胞72小时后与四唑盐处理。并测定OD450 - OD650值。

Western Blotting

Western Blotting

Western blot analysis of extracts from human dermal fibroblasts untreated or treated with hIGF-I for 10 minutes, using Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (upper) and Akt1 (C73H10) Rabbit mAb #2938 (lower).Western免疫印迹。用Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (上图) 和 Akt1 (C73H10) Rabbit mAb #2938 (下图) 研究未经处理的和经 hIGF-I处理10 min的皮肤成纤维细胞的细胞提取液。

Endotoxin

Less than 0.01 ng endotoxin/1 μg hIGF-I.

内毒素含量:小于0.01 ng /1 μg hIGF-I。

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hIGF-I. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

有载体: 每微克hIGF-I蛋白溶解在包含 100 mM NaCl 和 20 μg BSA的柠檬酸盐(pH 3.0)溶液中,并通过 0.22 μm 滤膜冻干。

无载体: 每微克hIGF-I蛋白溶解在包含 100 mM NaCl 的柠檬酸盐(pH 3.0)溶液中,并通过 0.22 μm 滤膜冻干。

Background

Most circulating endocrine acting IGF-I is produced by hepatocytes, and paracrine or autocrine acting IGF-I is produced by defined cell types within specific tissues (1,2). Many neoplastic cells produce IGF-I, which regulates a number of cellular processes including energy metabolism, proliferation, and cell survival (3,4). IGF-I activity is regulated by one or more of the six extracellular IGF-binding proteins (IGFBPs). IGFBPs bind to IGF-I and most inhibit IGF-I binding to IGF-I receptor (IGFIR) (1,2). Some IGFBPs may increase cell responses to IGF-I. Binding of IGF-I to IGFIR activates the Akt, JNK, and Erk pathways (2). IGF-I and IGFIR are frequently expressed by cancer cells and may contribute to the proliferation and viability of a number of cancer types (1,2).

大多数的循环的内分泌IGF-I是通过肝细胞产生的, 旁分泌或自分泌的IGF-I 是由特定细胞类型在特定的组织中产生(1,2)。 许多肿瘤细胞能产生IGF-I而调控很多的细胞活动,包括能量代谢、细胞增殖和细胞存活(3,4)。 IGF-I的活性是通过六个胞外IGF结合蛋白(IGFBPs)中的一个或多个共同调控。 IGFBPs结合到IGF-I上抑制IGF-I 和IGF-I 受体 (IGFIR)的结合 (1,2)。有些IGFBPs 能加强细胞对IGF-I的响应。IGF-I 结合到 IGFIR上激活了 Akt, JNK和Erk 信号通路 (2). IGF-I 和 IGFIR 通常被癌细胞频繁的表达,可能对某些种类的癌细胞的增殖和生存能力有重要的作用(1,2)。

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products


For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0

该产品暂无评论!

我要参与评论 :

如要参与评论请先登录网站

还没有网站账户?去注册一下吧

Products

 

Applications